Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without ISA 720 Adjuvant in Healthy Adults
NCT02743455Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2016
- Primary completion
- Mar 2018
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MVA-BN Yellow Fever Vaccine in yellow fever (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Grade 3 local, systemic or laboratory toxicities, continuous Grade 2 or greater local reactogenicity, Adverse Events of Special Interest and 7 more. Started Jul 2016; status: completed.
02
Drugs
MVA-BN Yellow Fever Vaccine
03
Conditions
yellow fever
Beyond the preview
Go deeper on NCT02743455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02743455.